科兴制药：人干扰素α1b吸入溶液已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单

Core Viewpoint - The announcement by the company regarding its inhalation solution for human interferon α1b being included in the list of breakthrough therapies by the National Medical Products Administration indicates a significant step in addressing respiratory syncytial virus (RSV) infections in children, although it will not have a major impact on the company's recent performance [1] Group 1: Product Development - The inhalation solution is specifically designed for children and is administered via nebulization, allowing the active ingredient to reach the site of infection more quickly [1] - The indication for the product is for pediatric lower respiratory tract infections caused by RSV, including pneumonia and bronchiolitis [1] - As of the announcement date, the product is in the Phase III clinical trial stage [1] Group 2: Market Context - According to a study published in The Lancet, there were 33 million cases of acute lower respiratory infections caused by RSV in children under five globally in 2019 [1] - The inclusion of the product in the breakthrough therapy list reflects its potential significance in the market, although future research progress, results, and competitive landscape remain uncertain [1]